Journey to the Center of the Vape – Part 1

Sep 26, 2019 | Blogs, Food / Beverage | 0 comments

The safety of vaping has recently become a topic of concern. The public wants answers about the safety of these products. Health authorities are scrambling to find the cause of the mysterious vaping illness that has been seen in hundreds of cases across the U.S., and that has caused multiple deaths.

Current news highlights related to recent cases:

Vaping has been around for years. It is too soon to know whether the recent cases are a new type of outbreak or something common that is just being seen through a lens of heightened awareness. The question remains: What is causing this illness?

Is investigating vitamin E acetate or polyethylene glycol the right focus? What about the questions surrounding the use of tetrahydrocannabinol (THC) as an ingredient in these e-cigarettes? Is mixing THC and nicotine to blame? The search for answers continues.

It makes sense to look at how an outbreak like this could happen. How could something unsafe make it into vaping products? One possible contributor to the situation is the lack of regulations around ingredients in both tobacco and cannabis vaping products. There is little transparency around ingredient labeling and few restrictions on additives. In an effort to further protect children, the FDA has announced plans to ban all non-tobacco e-cigarettes.

Another piece of the puzzle is the increase in counterfeit and illegal vaping products that have infected the market. Products are tampered with and adulterated, without consideration for the user’s safety. For instance, Wisconsin police reported a drug operation that was filling 3000-5000 illegal THC-infused vape cartridges a day for 2 years! Also, extremely concerning is that the THC potency of these products was 157 times higher than indicated on the labels. Imagine someone purchasing a vape pen from what they assume is a safe and reputable vendor (who follows strict testing protocols) only to find that it’s laced with synthetic cannabinoids, or worse, fentanyl.  

Other states may soon follow Hawaii’s lead in regulating CBD products, now that the risk of vaping illness is very real. This might also impact CBD-infused drinks found on shelves in established institutions—due to a lack of testing to demonstrate product safety. It will be interesting to see how regulations evolve. Will the rest of the world follow India and ban e-cigarettes entirely, too?

As analytical scientists, we want to understand what about the vaping chemistry is causing injury.  Is it a single toxic compound, or a mixture of substances? Is there a mechanism or trace-level compound that we’re not examining?

Stay tuned for part 2 of this piece where we discuss vaping chemistry and share what we found when we tested several commercial vape products.

As of the writing of this article, these were the most up to date facts and figures.


 

 

Overcoming uncertainty in your PFAS analysis

Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.

6 Signs it’s time for a new vendor

A lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.

Plasmid manufacturing: Setting up your CGT programs for success

Plasmid DNA serves a variety of purposes, from critical starting material for proteins, mRNA, viral vectors, and drug substances. Below, Dr. Emma Bjorgum, the Vice President of Client Services of the DNA Business Unit at Aldevron and an expert in plasmid manufacturing, provided insights into the process and an outlook on the future.

Posted by

I play an active role in supporting cannabis (marijuana and hemp) applications at SCIEX. I have more than 30 years of experience owning and operating contract labs in the environmental and bioanalytical markets. I've been part of the SCIEX family since 2011. I started as a field application chemist, and today I'm a market development manager for the North America team. Helping customers like you with your analytical challenges and educating the market on the many possibilities of LC-MS/MS systems, is my passion.

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial